IU1

Overview

IU1 is a selective, reversible USP14 inhibitor with an IC 50 of 4-5 μM. IU1 binds USP14 ’s catalytic cleft to block deubiquitinase activity . IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux , reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells . IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis , and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance . IU1 can be used for the research of Alzheimer’s disease, follicular thyroid cancer , ischemic stroke, cervical cancer , and neurodegenerative disease.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Thyroid Cancer | Products > Disease Areas > Thyroid Disease | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Deubiquitinase | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-13817
• CAS No.: 314245-33-5
• Molecular Formula: C18H21FN2O
• Molecular Weight: 300.37
• Purity: 99.30%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.67 mg/mL (5.56 mM); Clear solution
• Availability: In-stock

Source

Original product source